Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1877 |
| INN | None |
| Status | Terminated |
| Drug code(s) | Aurograb |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Fragment |
| Format details | scFv |
| Isotype (Fc) | None |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | S. aureus ABC transporter GrfA |
| Indications of clinical studies | Methicillin-resistant Staphylococcal infections |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | November 15, 2002 |
| Start of Phase 2 | |
| Start of Phase 3 | January 15, 2004 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Novartis Pharmaceuticals |
| Licensee/Partner | None |
| Comments about company or candidate | Novartis acquired NeuTec A review of Phase 2 data indicated a lack of efficacy as an add-on therapy to antibiotics; NCT00217841 is listed as a Phase 3 study |
| Full address of company | Basel, Switzerland Europe Switzerland https://www.novartis.com/contacts |
Target in https://patents.google.com/patent/US20080171054A1/en
| Anticipated events | None |
| Factor(s) contributing to discontinuation | Lack of efficacy |